Guidant DES Strategy Will Be Guided By Bare-Metal Stent Experience
This article was originally published in The Gray Sheet
Executive Summary
Guidant will support its initial drug-eluting stent PMA submission with the 975-patient FUTURE IV randomized, pivotal trial, slated to begin at up to 70 sites in the second quarter of 2004
You may also be interested in...
Guidant Rethinks Everolimus-Eluting Stent Platform Strategy, Timeframes
Guidant acknowledges that its initial drug-eluting stent may have to be a cobalt-chromium, durable-polymer stent if design changes to the bioabsorbable-polymer Champion require renewed preclinical or clinical testing
Guidant Rethinks Everolimus-Eluting Stent Platform Strategy, Timeframes
Guidant acknowledges that its initial drug-eluting stent may have to be a cobalt-chromium, durable-polymer stent if design changes to the bioabsorbable-polymer Champion require renewed preclinical or clinical testing
Cypher Revenue Stream Counters Some DES Damage To Guidant Stent Sales
Guidant's co-promotion and catheter supply agreements with Cordis generated revenue of $21 mil. in Q1, slightly assuaging the impact of drug-eluting stents on bare-metal sales